Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock

Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and
Series A Convertible Preferred Stock

NEW YORK, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc.
(Nasdaq:VTUS) announced today that it is concurrently offering to sell,
subject to market and other conditions, (i) shares of its common stock in an
underwritten public offering, and (ii) shares of its Series A Convertible
Preferred Stock ("Series A") in a separate underwritten public offering. The
Series A is non-voting and each share of Series A is convertible into 10
shares of Ventrus common stock, provided that conversion will be prohibited
if, as a result, the holder and its affiliates would own more than 9.98% of
the total number of Ventrus shares of common stock then outstanding. All of
the shares in these offerings are to be sold by Ventrus. Ventrus also intends
to grant the underwriter a 30-day option to purchase up to an additional 15%
of the shares of common stock sold in the common stock public offering to
cover over-allotments, if any.

William Blair & Company, L.L.C. is acting as the sole underwriter of these
offerings.

Each of these offerings is being made pursuant to an effective shelf
registration statement previously filed with the U.S. Securities and Exchange
Commission. This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Any offer, if at all, will
be made only by means of a prospectus supplement and accompanying prospectus
forming a part of the effective registration statement, copies of which may be
obtained, when available, from William Blair & Company, L.L.C. at 222 West
Adams Street, Chicago, IL 60606, Attention: Prospectus Department, by
telephone at (800) 621-0687, or by email at prospectus@williamblair.com.

About Ventrus Biosciences

Ventrus is a development stage pharmaceutical company focused on the
development of late-stage prescription drugs for gastrointestinal problems,
specifically anal disorders. Our lead product is topical diltiazem (VEN 307)
for the treatment of anal fissures, for which the first Phase 3 trial was
initiated in November 2010, and reported positive top line results in May
2012. The second Phase 3 trial began enrollment in the fourth quarter of 2012
and is ongoing. Our product candidate portfolio also includes topical
phenylephrine (VEN 308) intended to treat fecal incontinence. VEN 307 and VEN
308 are two molecules that were previously approved and marketed for other
indications and that have been formulated into our in-licensed proprietary
topical treatments for these new gastrointestinal indications.

Please Note: The information provided herein contains estimates and other
forward-looking statements regarding future events. Such statements are just
predictions and are subject to risks and uncertainties that could cause the
actual events or results to differ materially. These risks and uncertainties
include, among others: our ability to complete the offerings, including the
satisfaction of the closing conditions for each offering; our use of the
anticipated proceeds from the offerings; the components, timing, cost and
results of clinical trials and other development activities involving our
product candidates; the unpredictability of the clinical development of our
product candidates and of the duration and results of regulatory review of
those candidates by the FDA and foreign regulatory authorities; the
unpredictability of the size of the markets for, and market acceptance of, any
of our products; our anticipated capital expenditures, our estimates regarding
our capital requirements, and our need for future capital; our reliance on our
lead product candidate, VEN 307; our ability to retain and hire necessary
employees and to staff our operations appropriately; and the possible
impairment of, or inability to obtain, intellectual property rights and the
costs of obtaining such rights from third parties. The reader is referred to
the documents that we file from time to time with the Securities and Exchange
Commission.

CONTACT: Ventrus Biosciences, Inc.
         David Barrett
         646-706-5208
         dbarrett@ventrusbio.com
        
         Argot Partners
         David Pitts
         212-600-1902
         david@argotpartners.com
 
Press spacebar to pause and continue. Press esc to stop.